FilingSEC EDGAR8-K
Ocugen Initiates Phase 3 Dosing for OCU410 and Provides Clinical Update
· SEC accepted
StageClinical Trial in Progress
Filing content
The company initiated dosing in the Phase 3 trial for OCU410 and reported that the DMC recommended continuing the OCU410ST study to obtain 8-month follow-up data.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…